Researchers from the Ocean University of China described XZ-8078, a new dual-target protein degrader that simultaneously targets PARP1 and IKZF3, offering a potential strategy to enhance antitumor activity through coordinated pathway inhibition.

Shenzhen Targetrx Inc. has patented proteolysis targeting chimeras (PROTACs) comprising cereblon ligands coupled to a hepatocyte growth factor receptor (HGFR, MET)-targeting moiety via linker acting as HGFR degradation inducers potentially useful for the treatment of cancer.

Hinova Pharmaceuticals Inc. has patented new molecular glue degraders comprising E3 ubiquitin-protein ligase binding agents acting as proto-oncogene Vav (VAV1) degradation inducers. As such, they are reported to be potentially useful for the treatment of autoimmune diseases, inflammatory disorders and cancer.